肝细胞癌的经皮治疗:现状与创新
经皮治疗肝细胞癌(HCC)涵盖单极射频消融、多双极射频消融、微波消融、冷冻消融和不可逆电穿孔等技术。射频消融与手术切除和肝移植并列为肝硬化背景下小于5厘米HCC的主要根治性治疗之一,但消融与肝切除在小于3至5厘米HCC中的各自作用仍存争议。消融方法的创新可能有助于有效治疗最初被认为「不可消融」的早期HCC,并可能在某些情况下将消融标准扩展至早期HCC之外。
要点
- 射频消融是肝硬化背景下小于5厘米HCC的主要根治性治疗之一。
- 消融与肝切除在小于3至5厘米HCC中的各自作用仍存争议。
- 消融方法创新可能将根治性治疗扩展至更多患者。
核心结论
- 经皮消融是早期HCC根治性治疗的重要组成部分,方法创新可能扩展消融适应证并惠及更多患者。
研究设计与样本
- 综述,总结经皮治疗HCC的技术现状与创新。
主要发现
- 经皮治疗HCC包括单极射频消融、多双极射频消融、微波消融、冷冻消融和不可逆电穿孔等技术。
- 射频消融与手术切除和肝移植并列为肝硬化背景下小于5厘米HCC的主要根治性治疗之一。
- 消融与肝切除在肝硬化背景下小于3至5厘米HCC中的各自作用仍存争议。
- 消融方法创新可能有助于有效治疗最初被认为「不可消融」的早期HCC,并可能在某些情况下将消融标准扩展至早期HCC之外。
临床怎么用
- 按早期HCC治疗算法,经皮消融可用作肝移植的桥接治疗,或先行经皮治疗、若患者复发再行移植。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Percutaneous treatment of hepatocellular carcinoma (HCC) encompasses a vast range of techniques, including monopolar radiofrequency ablation (RFA), multibipolar RFA, microwave ablation, cryoablation and irreversible electroporation. RFA is considered one of the main curative treatments for HCC of less than 5 cm developing on cirrhotic liver, together with surgical resection and liver transplantation. However, controversies exist concerning the respective roles of ablation and liver resection for HCC of less than 3 to 5 cm on cirrhotic liver. In line with the therapeutic algorithm of early HCC, percutaneous ablation could also be used as a bridge to liver transplantation or in a sequence of upfront percutaneous treatment, followed by transplantation if the patient relapses. Moreover, several innovations in ablation methods may help to efficiently treat early HCC, initially considered as "non-ablatable", and might, in some cases, extend ablation criteria beyond early HCC, enabling treatment of more patients with a curative approach.
引用
- Nault JC, Sutter O, Nahon P, et al. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. J Hepatol. 2017. PMID: 29031662. doi:10.1016/j.jhep.2017.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。